Tumor markers are biological substances that are produced by cancer cells or the body's response to cancer. Ideal tumor markers should be highly specific, sensitive, correlate with tumor stage/mass, and predict prognosis. Recent advances include new genetic and viral biomarkers. Tumor markers can be classified as hormones, oncofetal antigens, enzymes, tumor-associated proteins, receptors, and genetic markers. Oncogenes like RAS and C-myc can also serve as markers when mutated or translocated. Establishing biomarkers requires understanding how small molecular changes disrupt cellular functions and cancer initiation.
Tumor markers are substances produced by tumor cells or the body's response to tumors that can be detected and measured in bodily fluids or tissues. They can help diagnose certain cancers, distinguish between benign and malignant tumors, monitor treatment response and detect recurrence. However, no single tumor marker is perfect as tumor marker levels can also be elevated in some non-cancerous conditions.
Tumor markers are substances produced by tumors or the body's response to tumors that can help detect and monitor cancer. Alpha-fetoprotein (AFP) is elevated in hepatocellular carcinoma and germ cell tumors. It is useful for diagnosis, staging, prognosis, and monitoring treatment response in HCC and germ cell tumors. Carcinoembryonic antigen (CEA) is elevated in various cancers including colorectal cancer. CEA levels correlate with tumor stage and burden and can help monitor treatment response and detect recurrence, though it lacks sensitivity and specificity for screening and diagnosis.
This document discusses newer tumor markers that can be used for cancer diagnosis, prognosis, and monitoring treatment. It describes various types of biochemical entities that serve as tumor markers, including nucleic acids, proteins, sugars, lipids, and whole tumor cells. Specific examples of tumor markers are discussed, such as enzymes, hormones, oncofetal antigens, tumor-associated proteins, carbohydrate antigens, and genetic markers. The ideal properties of tumor markers and their clinical applications are also summarized.
Tumour Markers are substances present in the tumour, produced by the tumour or by the host as a response to the presence of the tumour, providing information about biological characteristics of the tumour. these tumour markers may specific for the tissue but often get elevated in neoplastic as well non-neoplastic lesions, further Various analytical platforms available for serum tumour markers lack standardisation. These factors add to interpretative challenges in serum tumour markers
Tumor markers are substances produced by cancer cells or other cells in response to cancer that can be detected in bodily fluids or tissues. The ideal tumor marker would be highly sensitive and specific to a cancer, produced early in cancer progression, and correlated with tumor burden. Common tumor markers include AFP for liver and germ cell cancers, CEA for gastrointestinal cancers, PSA for prostate cancer, CA125 for ovarian cancer, and calcitonin for thyroid cancer. Tumor markers have applications in cancer screening, diagnosis, staging, determining prognosis, monitoring treatment response, and detecting recurrence.
This document discusses tumor markers, which are substances that can indicate the presence of cancer. It defines tumor markers as products of cancer cells or the body's response to cancer that are usually found in blood or urine. However, tumor markers alone cannot diagnose or rule out cancer. The document then classifies different types of tumor markers such as antigens, enzymes, hormones, oncofetal proteins, and tumor-associated antigens. It explains how tumor markers can be used for cancer screening, diagnosis, determining prognosis and treatment effectiveness, and detecting cancer recurrence. Key tumor markers are discussed for different cancer types.
Tumor Biomarkers For Screening, Progression and Prognosis Vivek Misra
Tumor markers are substances that can be found in the body (usually in the blood or urine) when cancer is present. Along with other tests, tumor markers can be used to help show if cancer is present, to determine the type of cancer, and in some cases to help show if treatment is working. Some of the more common tumor markers are discussed here.
Tumor markers are biomarkers found in blood, urine, or tissues that can indicate the presence of cancer when elevated. They can be produced directly by tumors or other cells in response to tumors. While tumor marker assays help with cancer staging and treatment, they are usually not definitive diagnostic tests and biopsy is required for diagnosis. Tumor markers include proteins, peptides, and carbohydrates and can be used for cancer screening, monitoring recurrence, diagnosis, staging, prognosis, evaluating treatment effectiveness, and as companion diagnostics. Commonly used tumor markers include alpha fetoprotein, CA15-3, CA27-29, CA19-9, and CA-125.
Tumor markers are substances produced by tumor cells or the body's response to tumors that can be detected and measured in bodily fluids or tissues. They can help diagnose certain cancers, distinguish between benign and malignant tumors, monitor treatment response and detect recurrence. However, no single tumor marker is perfect as tumor marker levels can also be elevated in some non-cancerous conditions.
Tumor markers are substances produced by tumors or the body's response to tumors that can help detect and monitor cancer. Alpha-fetoprotein (AFP) is elevated in hepatocellular carcinoma and germ cell tumors. It is useful for diagnosis, staging, prognosis, and monitoring treatment response in HCC and germ cell tumors. Carcinoembryonic antigen (CEA) is elevated in various cancers including colorectal cancer. CEA levels correlate with tumor stage and burden and can help monitor treatment response and detect recurrence, though it lacks sensitivity and specificity for screening and diagnosis.
This document discusses newer tumor markers that can be used for cancer diagnosis, prognosis, and monitoring treatment. It describes various types of biochemical entities that serve as tumor markers, including nucleic acids, proteins, sugars, lipids, and whole tumor cells. Specific examples of tumor markers are discussed, such as enzymes, hormones, oncofetal antigens, tumor-associated proteins, carbohydrate antigens, and genetic markers. The ideal properties of tumor markers and their clinical applications are also summarized.
Tumour Markers are substances present in the tumour, produced by the tumour or by the host as a response to the presence of the tumour, providing information about biological characteristics of the tumour. these tumour markers may specific for the tissue but often get elevated in neoplastic as well non-neoplastic lesions, further Various analytical platforms available for serum tumour markers lack standardisation. These factors add to interpretative challenges in serum tumour markers
Tumor markers are substances produced by cancer cells or other cells in response to cancer that can be detected in bodily fluids or tissues. The ideal tumor marker would be highly sensitive and specific to a cancer, produced early in cancer progression, and correlated with tumor burden. Common tumor markers include AFP for liver and germ cell cancers, CEA for gastrointestinal cancers, PSA for prostate cancer, CA125 for ovarian cancer, and calcitonin for thyroid cancer. Tumor markers have applications in cancer screening, diagnosis, staging, determining prognosis, monitoring treatment response, and detecting recurrence.
This document discusses tumor markers, which are substances that can indicate the presence of cancer. It defines tumor markers as products of cancer cells or the body's response to cancer that are usually found in blood or urine. However, tumor markers alone cannot diagnose or rule out cancer. The document then classifies different types of tumor markers such as antigens, enzymes, hormones, oncofetal proteins, and tumor-associated antigens. It explains how tumor markers can be used for cancer screening, diagnosis, determining prognosis and treatment effectiveness, and detecting cancer recurrence. Key tumor markers are discussed for different cancer types.
Tumor Biomarkers For Screening, Progression and Prognosis Vivek Misra
Tumor markers are substances that can be found in the body (usually in the blood or urine) when cancer is present. Along with other tests, tumor markers can be used to help show if cancer is present, to determine the type of cancer, and in some cases to help show if treatment is working. Some of the more common tumor markers are discussed here.
Tumor markers are biomarkers found in blood, urine, or tissues that can indicate the presence of cancer when elevated. They can be produced directly by tumors or other cells in response to tumors. While tumor marker assays help with cancer staging and treatment, they are usually not definitive diagnostic tests and biopsy is required for diagnosis. Tumor markers include proteins, peptides, and carbohydrates and can be used for cancer screening, monitoring recurrence, diagnosis, staging, prognosis, evaluating treatment effectiveness, and as companion diagnostics. Commonly used tumor markers include alpha fetoprotein, CA15-3, CA27-29, CA19-9, and CA-125.
Breast cancer & biomarkers, their types, novelty of breast cancer biomarkers. Detailed study of her2, p53, BRCA1, BRCA2, DPD, 21-Gene signature, 70-Gene signature, cd106, vcam1, nlr, bFGF, mammaglobin, ER, PR, CEA. Pthological samples for biomarkers test, Ranges of various biomarkers, breast cancer diagnosis, prognosis, occurance, selection of breast caner treatment like targeted therapy.
1. Several molecular pathways are involved in breast cancer pathogenesis, including steroid hormone receptors, HER2/neu, cell cycle proteins, and growth factors.
2. Risk factors for breast cancer include increasing age, female gender, family history, genetic mutations, personal history of breast cancer or other breast diseases, reproductive factors, and hormone use.
3. High risk patients are identified using tools like the Gail model and managed through increased screening including breast self-exams, clinical exams, mammograms, and MRI. Preventive options include tamoxifen, raloxifen, and prophylactic surgeries.
Tumor markers are substances produced by tumor cells or the body's response to tumors that can be detected in blood, urine, or tissue. They can be used to screen for cancers, help diagnose cancer when the primary site is unknown, stage cancers, determine prognosis, and monitor treatment effectiveness. The most widely accepted tumor markers are prostate-specific antigen for prostate cancer screening and alpha-fetoprotein plus ultrasound for screening for hepatocellular carcinoma in endemic areas. Elevated levels of markers like gastrin and insulin are diagnostic for certain neuroendocrine tumors.
This document discusses various methods for cancer diagnosis, including radiological, cytological, histological, and molecular diagnosis. Radiological methods like X-ray, ultrasound, CT, and MRI can help detect cancers non-invasively. Cytological diagnosis involves examining cells through methods like fine needle aspiration. Histological diagnosis requires tissue sampling through biopsy or surgery to examine cells under a microscope. Molecular diagnosis analyzes genetic changes involved in cancer. Tumor markers found in blood and tissues can also provide clues about certain cancer types.
Biomarkers can be used for screening, diagnosis, prognosis, and predicting response to treatment for cancer. In bladder cancer, screening biomarkers could identify high-risk groups but population screening may lead to many false positives. Diagnostic biomarkers are needed because hematuria is non-specific, and cystoscopy is expensive. Prognostic biomarkers help determine disease course as response can vary between patients with similar pathology. Predictive biomarkers identify subgroups likely to benefit from specific therapies.
Tumor markers are biological substances released by tumor cells or the body in response to tumors. They can be detected in bodily fluids and indicate the presence or progression of cancer. While no single tumor marker is perfect, they can be useful for screening, diagnosis, staging, prognosis, monitoring treatment response, and detecting recurrence. Common tumor markers include CEA, AFP, CA19-9, PSA, CA125, and hormone receptors. A variety of detection methods exist. While beneficial, tumor markers also have limitations like elevated levels in benign conditions and lack of presence in some cancer types. Continual research aims to improve tumor marker tests and discover new markers.
Target Audience: Oncology fellows and Oncologists
Carcinoma of unknown primary is a challenging scenario often encountered in Oncology practice. This slide presentation discusses favorable and unfavorable presentations of CUP and it's management
1. Tumor markers are substances produced by cancer cells or the body's response to cancer that can be detected and measured in blood, urine, or tissue samples.
2. Common tumor markers include CEA, AFP, CA19-9, CA125, PSA, and HER2/neu. They are used to help diagnose cancer, determine prognosis, guide treatment decisions, and monitor response to treatment.
3. However, tumor marker levels can also be elevated in non-cancerous conditions, so they are not definitive cancer diagnoses on their own and must be interpreted along with other clinical information.
Tumor markers
Many cancers are associated with the abnormal production of some molecules which can be measured in plasma. These molecules are known as tumor markers.
A good tumor maker should have those properties:
1. A tumor marker should be present in or produced by tumor itself.
2. A tumor marker should not be present in healthy tissues.
3. Plasma level of a tumor marker should be at a minimum level in healthy subjects and in benign conditions.
4. A tumor marker should be specific for a tissue, it should have different immunological properties when it is synthesized in other tissues.
5. Plasma level of the tumor marker should be in proportion to the both size of the tumor and the activity of the tumor.
6. Half-life of a tumor should not be very long
7. A tumor marker should be present in plasma at a detectable level, even though tumor size is very small
Tumor markers are proteins or mutated proteins that can indicate the presence of cancer. They are useful for screening, diagnosis, monitoring treatment and detecting recurrence, though none are sufficiently sensitive and specific for screening alone. Tumor markers associated with cell proliferation, differentiation, metastasis and other tumor events can provide information about cancer. While not diagnostic, they are helpful for treatment monitoring given their limitations. Proper use requires understanding their sensitivity, specificity and potential causes of false positives.
Tumor markers are substances produced by tumors or the host body in response to tumors. They can be used to detect cancers, determine cancer prognosis, and monitor cancer treatment effectiveness. Some key tumor markers discussed in the document include:
- AFP which is used to detect hepatocellular carcinoma and testicular cancer.
- CEA which is used to detect colorectal cancer recurrence. Rising CEA levels may indicate cancer recurrence while stable levels indicate remission.
- CA125 which is used to detect ovarian and endometrial cancers.
- PSA which is used to screen, stage, and monitor prostate cancer recurrence and treatment.
- HCG which is used to detect germ
Tumour markers are substances that are produced by tumour cells or the body's response to tumours that can be detected and measured in blood, urine, or body tissues. They can be used for screening, diagnosis, staging, detecting recurrence, and monitoring treatment response. However, tumour markers have limitations as they are not always tumour-specific and levels can be elevated in benign conditions. The main uses of common tumour markers are monitoring disease in patients with known cancers like CEA for colorectal cancer, PSA for prostate cancer, and AFP and HCG for germ cell tumours.
This document discusses liquid biopsy, a non-invasive technique to detect tumor biomarkers shed into body fluids like blood. It can identify circulating tumor cells, circulating tumor DNA, exosomes, and newly, tumor educated platelets. Liquid biopsy offers advantages over tissue biopsy like being less invasive, allowing repeated sampling over time. While sensitivity remains a limitation, liquid biopsy shows promise for early cancer detection, monitoring treatment response and tumor evolution, and assessing tumor heterogeneity. The document reviews technologies to analyze various biomarkers and potential clinical applications of liquid biopsy.
The document discusses tumor markers, which are substances produced by cancer cells that can be used to identify cancers. It provides objectives for lectures on tumor markers, including defining tumor markers, identifying their clinical value in cancer management, and summarizing major tumor types and their associated markers. Characteristics of ideal tumor markers and examples like AFP, CA-125, CEA, beta-hCG, and PSA are also examined.
This document discusses the Gleason grading system for prostate cancer. It provides details on the original Gleason patterns from 1 to 5 based on tumor architecture, with pattern 1 being the most differentiated and pattern 5 being undifferentiated. The Gleason score is determined by adding the primary and secondary patterns. The document reviews reporting of Gleason scores for different specimen types like biopsies and radical prostatectomies. It also discusses modifications to the Gleason system over time with new discoveries in prostate cancer.
This document provides an overview of cancer biology, covering topics such as the definition of cancer, types of cancers like carcinomas and sarcomas, common cancers by incidence rate, key characteristics of specific cancers like lung cancer and colon cancer, cancer genetics including oncogenes and tumor suppressor genes, hallmarks of cancer, and the process of metastasis. It includes descriptions, risk factors, images and literature references.
Colorectal cancer is the second leading cause of cancer death in western countries. Early detection through screening can prevent over 50% of deaths, but screening rates remain low. Current noninvasive screening methods like fecal occult blood tests (FOBT) have limitations in sensitivity and specificity. Blood markers like CEA, LASA, and CA19-9 are not adequate screening tools. Stool markers show more promise, like immunochemical FOBT, colonocytes, and stool DNA testing which can detect mutations. While promising, stool DNA testing needs more research on cost effectiveness and patient acceptance before being recommended for general screening. Overall, no single marker is sufficient for screening and early detection remains a challenge.
This document defines key terms related to cancer biomarkers. It describes cancer as abnormal cell growth and discusses cancer staging and tumor markers. Biomarkers are defined as indicators of biological processes that can be tested from bodily fluids or tissues. Common tumor markers are described, including alpha-fetoprotein, cancer antigen 125, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. The roles of these markers in cancer screening, diagnosis, staging, prognosis, and monitoring treatment are summarized.
Tumor markers are biological substances released by tumor cells or the body in response to tumors that can be detected at higher-than-normal levels in bodily fluids. They provide information about cancer screening, diagnosis, staging, prognosis, therapy, and monitoring. No single tumor marker is perfect, but some common and useful ones include CEA for colorectal cancer, AFP for liver and testicular cancers, CA19-9 for pancreatic cancer, PSA for prostate cancer, and CA125 for ovarian cancer. Newer markers based on DNA, RNA, and proteins are continually being discovered and evaluated to improve cancer detection and management.
Breast cancer & biomarkers, their types, novelty of breast cancer biomarkers. Detailed study of her2, p53, BRCA1, BRCA2, DPD, 21-Gene signature, 70-Gene signature, cd106, vcam1, nlr, bFGF, mammaglobin, ER, PR, CEA. Pthological samples for biomarkers test, Ranges of various biomarkers, breast cancer diagnosis, prognosis, occurance, selection of breast caner treatment like targeted therapy.
1. Several molecular pathways are involved in breast cancer pathogenesis, including steroid hormone receptors, HER2/neu, cell cycle proteins, and growth factors.
2. Risk factors for breast cancer include increasing age, female gender, family history, genetic mutations, personal history of breast cancer or other breast diseases, reproductive factors, and hormone use.
3. High risk patients are identified using tools like the Gail model and managed through increased screening including breast self-exams, clinical exams, mammograms, and MRI. Preventive options include tamoxifen, raloxifen, and prophylactic surgeries.
Tumor markers are substances produced by tumor cells or the body's response to tumors that can be detected in blood, urine, or tissue. They can be used to screen for cancers, help diagnose cancer when the primary site is unknown, stage cancers, determine prognosis, and monitor treatment effectiveness. The most widely accepted tumor markers are prostate-specific antigen for prostate cancer screening and alpha-fetoprotein plus ultrasound for screening for hepatocellular carcinoma in endemic areas. Elevated levels of markers like gastrin and insulin are diagnostic for certain neuroendocrine tumors.
This document discusses various methods for cancer diagnosis, including radiological, cytological, histological, and molecular diagnosis. Radiological methods like X-ray, ultrasound, CT, and MRI can help detect cancers non-invasively. Cytological diagnosis involves examining cells through methods like fine needle aspiration. Histological diagnosis requires tissue sampling through biopsy or surgery to examine cells under a microscope. Molecular diagnosis analyzes genetic changes involved in cancer. Tumor markers found in blood and tissues can also provide clues about certain cancer types.
Biomarkers can be used for screening, diagnosis, prognosis, and predicting response to treatment for cancer. In bladder cancer, screening biomarkers could identify high-risk groups but population screening may lead to many false positives. Diagnostic biomarkers are needed because hematuria is non-specific, and cystoscopy is expensive. Prognostic biomarkers help determine disease course as response can vary between patients with similar pathology. Predictive biomarkers identify subgroups likely to benefit from specific therapies.
Tumor markers are biological substances released by tumor cells or the body in response to tumors. They can be detected in bodily fluids and indicate the presence or progression of cancer. While no single tumor marker is perfect, they can be useful for screening, diagnosis, staging, prognosis, monitoring treatment response, and detecting recurrence. Common tumor markers include CEA, AFP, CA19-9, PSA, CA125, and hormone receptors. A variety of detection methods exist. While beneficial, tumor markers also have limitations like elevated levels in benign conditions and lack of presence in some cancer types. Continual research aims to improve tumor marker tests and discover new markers.
Target Audience: Oncology fellows and Oncologists
Carcinoma of unknown primary is a challenging scenario often encountered in Oncology practice. This slide presentation discusses favorable and unfavorable presentations of CUP and it's management
1. Tumor markers are substances produced by cancer cells or the body's response to cancer that can be detected and measured in blood, urine, or tissue samples.
2. Common tumor markers include CEA, AFP, CA19-9, CA125, PSA, and HER2/neu. They are used to help diagnose cancer, determine prognosis, guide treatment decisions, and monitor response to treatment.
3. However, tumor marker levels can also be elevated in non-cancerous conditions, so they are not definitive cancer diagnoses on their own and must be interpreted along with other clinical information.
Tumor markers
Many cancers are associated with the abnormal production of some molecules which can be measured in plasma. These molecules are known as tumor markers.
A good tumor maker should have those properties:
1. A tumor marker should be present in or produced by tumor itself.
2. A tumor marker should not be present in healthy tissues.
3. Plasma level of a tumor marker should be at a minimum level in healthy subjects and in benign conditions.
4. A tumor marker should be specific for a tissue, it should have different immunological properties when it is synthesized in other tissues.
5. Plasma level of the tumor marker should be in proportion to the both size of the tumor and the activity of the tumor.
6. Half-life of a tumor should not be very long
7. A tumor marker should be present in plasma at a detectable level, even though tumor size is very small
Tumor markers are proteins or mutated proteins that can indicate the presence of cancer. They are useful for screening, diagnosis, monitoring treatment and detecting recurrence, though none are sufficiently sensitive and specific for screening alone. Tumor markers associated with cell proliferation, differentiation, metastasis and other tumor events can provide information about cancer. While not diagnostic, they are helpful for treatment monitoring given their limitations. Proper use requires understanding their sensitivity, specificity and potential causes of false positives.
Tumor markers are substances produced by tumors or the host body in response to tumors. They can be used to detect cancers, determine cancer prognosis, and monitor cancer treatment effectiveness. Some key tumor markers discussed in the document include:
- AFP which is used to detect hepatocellular carcinoma and testicular cancer.
- CEA which is used to detect colorectal cancer recurrence. Rising CEA levels may indicate cancer recurrence while stable levels indicate remission.
- CA125 which is used to detect ovarian and endometrial cancers.
- PSA which is used to screen, stage, and monitor prostate cancer recurrence and treatment.
- HCG which is used to detect germ
Tumour markers are substances that are produced by tumour cells or the body's response to tumours that can be detected and measured in blood, urine, or body tissues. They can be used for screening, diagnosis, staging, detecting recurrence, and monitoring treatment response. However, tumour markers have limitations as they are not always tumour-specific and levels can be elevated in benign conditions. The main uses of common tumour markers are monitoring disease in patients with known cancers like CEA for colorectal cancer, PSA for prostate cancer, and AFP and HCG for germ cell tumours.
This document discusses liquid biopsy, a non-invasive technique to detect tumor biomarkers shed into body fluids like blood. It can identify circulating tumor cells, circulating tumor DNA, exosomes, and newly, tumor educated platelets. Liquid biopsy offers advantages over tissue biopsy like being less invasive, allowing repeated sampling over time. While sensitivity remains a limitation, liquid biopsy shows promise for early cancer detection, monitoring treatment response and tumor evolution, and assessing tumor heterogeneity. The document reviews technologies to analyze various biomarkers and potential clinical applications of liquid biopsy.
The document discusses tumor markers, which are substances produced by cancer cells that can be used to identify cancers. It provides objectives for lectures on tumor markers, including defining tumor markers, identifying their clinical value in cancer management, and summarizing major tumor types and their associated markers. Characteristics of ideal tumor markers and examples like AFP, CA-125, CEA, beta-hCG, and PSA are also examined.
This document discusses the Gleason grading system for prostate cancer. It provides details on the original Gleason patterns from 1 to 5 based on tumor architecture, with pattern 1 being the most differentiated and pattern 5 being undifferentiated. The Gleason score is determined by adding the primary and secondary patterns. The document reviews reporting of Gleason scores for different specimen types like biopsies and radical prostatectomies. It also discusses modifications to the Gleason system over time with new discoveries in prostate cancer.
This document provides an overview of cancer biology, covering topics such as the definition of cancer, types of cancers like carcinomas and sarcomas, common cancers by incidence rate, key characteristics of specific cancers like lung cancer and colon cancer, cancer genetics including oncogenes and tumor suppressor genes, hallmarks of cancer, and the process of metastasis. It includes descriptions, risk factors, images and literature references.
Colorectal cancer is the second leading cause of cancer death in western countries. Early detection through screening can prevent over 50% of deaths, but screening rates remain low. Current noninvasive screening methods like fecal occult blood tests (FOBT) have limitations in sensitivity and specificity. Blood markers like CEA, LASA, and CA19-9 are not adequate screening tools. Stool markers show more promise, like immunochemical FOBT, colonocytes, and stool DNA testing which can detect mutations. While promising, stool DNA testing needs more research on cost effectiveness and patient acceptance before being recommended for general screening. Overall, no single marker is sufficient for screening and early detection remains a challenge.
This document defines key terms related to cancer biomarkers. It describes cancer as abnormal cell growth and discusses cancer staging and tumor markers. Biomarkers are defined as indicators of biological processes that can be tested from bodily fluids or tissues. Common tumor markers are described, including alpha-fetoprotein, cancer antigen 125, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. The roles of these markers in cancer screening, diagnosis, staging, prognosis, and monitoring treatment are summarized.
Tumor markers are biological substances released by tumor cells or the body in response to tumors that can be detected at higher-than-normal levels in bodily fluids. They provide information about cancer screening, diagnosis, staging, prognosis, therapy, and monitoring. No single tumor marker is perfect, but some common and useful ones include CEA for colorectal cancer, AFP for liver and testicular cancers, CA19-9 for pancreatic cancer, PSA for prostate cancer, and CA125 for ovarian cancer. Newer markers based on DNA, RNA, and proteins are continually being discovered and evaluated to improve cancer detection and management.
TUMOUR MARKERS AND CLINICAL EFFECTS OF TUMOR-1.pptxmwalunuym
This document discusses tumour markers and the clinical effects of cancer. It begins by outlining the objectives and providing an introduction to tumour markers. It then describes the clinical uses, ideal characteristics, and classification of tumour markers. The document discusses the local effects of tumours through compression, obstruction, destruction and other means. It also outlines some of the systemic effects of cancer, including cancer cachexia caused by cytokines, inflammation, and metabolic changes. In summary, the document provides an overview of tumour markers and how cancer can affect the body both locally and systemically.
This document discusses biomarkers in cancer detection and diagnosis. It defines biomarkers as molecules that indicate normal or abnormal biological processes and may signal diseases like cancer. Biomarkers can be found in tissues, blood, or other bodily fluids and include proteins, genes, RNA, carbohydrates, or viruses associated with certain cancers. Biomarkers are useful for early cancer detection, diagnosis, assessing prognosis, predicting treatment effectiveness, and identifying molecular drug targets. Several protein, DNA, and RNA biomarkers for cancers of the breast, ovary, prostate, bladder, oral cavity, colon, and HIV-associated cancers are discussed. Imaging techniques can also serve as cancer biomarkers by aiding screening, diagnosis, and monitoring treatment response.
Cancer is the second leading cause of death worldwide after cardiovascular disease. In India, an estimated 2.25 million people are living with cancer, with over 11 lakh new cases registered annually. Some key statistics for India include one woman dying of cervical cancer every 8 minutes and two women dying of breast cancer for every one diagnosed. Tumor markers are substances produced by cancerous tissues or the body in response to cancer that can help detect or monitor cancer. Some common tumor markers are CEA, AFP, CA125, and PSA. Tumor markers can be used for screening, diagnosis, staging, prognosis, and monitoring treatment effectiveness and recurrence. Characteristics of ideal tumor markers include cancer specificity, high sensitivity and specificity for detection
This document discusses tumor markers and their use in monitoring tumor response to therapy. It provides information on different types of tumor markers including proteins, enzymes, hormones, genetic markers and circulating tumor cells. Ideal tumor markers are highly sensitive and specific, correlate with tumor stage and prognosis, and can be used for screening, diagnosis, prognosis, monitoring treatment and detecting recurrence. Examples discussed include CEA, AFP, PSA, CA125 and circulating tumor cells. The Oncotype DX 21-gene recurrence score test and tissue polypeptide specific antigen are also summarized.
Tumor markers can play roles in early detection, diagnosis, prognosis, monitoring treatment response, and detecting recurrence of certain cancers. This document discusses various tumor markers including their reference ranges, associated cancers, clinical applications, and methods of detection. Key points covered include the roles of AFP for liver cancer screening, CEA and CA19-9 for colorectal cancer monitoring, PSA for prostate cancer screening and follow up, and CA125 for ovarian cancer treatment assessment and recurrence detection. The document also provides recommendations for optimal use of tumor marker tests.
This document defines various tumor markers and their clinical applications. It discusses commonly ordered tumor markers such as alpha-fetoprotein, cancer antigen 125, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. These markers can be used for cancer diagnosis, prognosis, and monitoring treatment effectiveness. However, tumor marker levels are not specific to cancer and can be elevated in certain non-cancerous conditions. Enzymes were among the first tumor markers identified but provide only nonspecific indications of malignancy.
This document provides an overview of molecular diagnostic methods for liver cancer. It discusses detecting cancer-related genes, genes of related viruses like HBV and HCV, and markers of liver cancer. Common markers are alpha-fetoprotein, GGT, and CA125. Detection methods include PCR, gene chips, radioimmunoassay, ELISA, and chemiluminescent, fluorescent, and electrochemiluminescent immunoassay systems. The document concludes that combining detection of multiple markers is more effective than single markers and will improve early diagnosis as methods advance.
Human cancer development, or oncogenesis, results from genetic changes in oncogenes and tumor suppressor genes. Oncogenes like Ras, Myc, and EGFR promote cancer when overexpressed, while tumor suppressors like p53 and Rb inhibit cancer when functioning normally. Genetic changes from carcinogens, radiation, viruses, or other sources can delete or mutate these genes, altering the control of mitosis and apoptosis and leading to uncontrolled cell growth and the multi-step development of tumors over time. Tumor markers in the blood can indicate the presence, severity, or progression of cancers and help guide treatment responses.
Tumor markers are proteins detected in blood that can indicate certain cancers. They are most useful for monitoring response to treatment and detecting early recurrence of cancer. With the exception of PSA, tumor markers lack sufficient accuracy for cancer screening. Some common tumor markers include CA 27.29 for breast cancer, CEA for colorectal cancer, and AFP and beta-hCG for germ cell tumors and liver cancer. While tumor markers can help manage cancer patients, no marker alone guarantees cure or determines treatment; clinical evaluation is also needed.
Cancer is caused by genetic mutations from carcinogens like chemicals, radiation, and viruses. Cancer cells show uncontrolled growth, loss of contact inhibition, and altered biochemistry. Tumor markers are proteins produced by or in response to cancer that can help detect and monitor cancers. Common tumor markers include AFP for liver cancer, CEA for colorectal cancer, and PSA for prostate cancer.
Use of Autoantibodies to detect the onset of breast cancerIsabelle Chiu
This document discusses using autoantibodies to detect the early onset of breast cancer. It begins by introducing breast cancer and some of the common screening and testing methods like mammograms, MRI, and biopsies. It then discusses how tumors produce tumor-associated antigens that the immune system recognizes through autoantibodies. The document analyzes several studies using techniques like Luminex bead arrays to test for autoantibodies against tumor antigens in breast cancer patients, finding autoantibodies against antigens like p53, HER2, and NY-ESO-1. It concludes that monitoring autoantibody profiles could help detect cancers patients are predisposed to before symptoms appear.
This document discusses various diagnostic tools used in oncology, including tumor markers, immunohistochemistry, immunocytology, cytogenetics, molecular diagnosis, and gene expression analysis. It provides details on tumor markers including their definition, classification, factors that affect serum levels, and indications for use. It also discusses immunohistochemistry in detail, covering tumor antigens, immunoreactivity, clinical applications for diagnosis, predicting therapy response and prognosis, and specific carcinoma markers like cytokeratins, CEA, and hormone receptors.
Tumor Markers include a wide range of biomacromolecules orchestrated in abundance fixation by a wide assortment of neoplastic cells. The markers could be endogenous results of exceptionally dynamic metabolic threatening cells or the results of recently turned on qualities, which stayed unexpressed in early life or recently obtained antigens at cell and sub-cell levels. The presence of tumor marker and their focus are identified with the beginning and development of dangerous tumors in patients. A perfect tumor marker ought to be profoundly delicate, explicit, dependable with high prognostic worth, organ particularity and it should relate with tumor stages. Be that as it may, none of the tumor markers answered to date has every one of these attributes. Inspite of these impediments, numerous tumor markers have indicated incredible clinical significance in checking adequacy of various methods of treatments during whole course of sickness in malignant growth patients. Moreover, assurance of markers additionally helps in early discovery of malignant growth repeat and in anticipation.
NEOPLASIA: Grading and Staging & Laboratory Diagnosis of CancerDr. Roopam Jain
This document discusses the grading and staging of tumors as well as the laboratory diagnosis of cancer. Grading is based on the microscopic appearance and differentiation of the tumor, while staging looks at how far the cancer has spread. Cancers are also classified by their degree of differentiation, from well-differentiated to poorly differentiated. Laboratory diagnosis involves histological examination of biopsies as well as tumor markers that can provide diagnostic or prognostic information.
Discuss the use of tumor markers in surgical practiceCHIZOWA EZEAKU
This document discusses the use of tumor markers in surgical practice. It defines tumor markers as substances present in or produced by a tumor that can be used to detect or monitor the presence of cancer. The document outlines the classification, clinical applications, limitations, and recent trends in the use of tumor markers. It provides examples of specific tumor markers used for various cancer types and recommendations for the optimal use and interpretation of tumor marker levels.
Cancer is characterized by uncontrolled cellular growth and proliferation that can spread to other parts of the body. It is caused by both external factors like chemicals, radiation, viruses and internal factors such as genetic mutations. Cancer development is driven by changes in oncogenes and tumor suppressor genes. Tumor markers are substances produced by cancer cells or the body in response to cancer that can be detected in bodily fluids or tissues and used to diagnose certain cancer types. Some common tumor markers are CEA for colon cancer, AFP for liver cancer, and PSA for prostate cancer.
Diagonsis of cancer through saliva.pptxZaidAhmad42
Human saliva is an ideal body fluid for developing non-invasive diagnostics. Saliva contains naturally-occurring nanoparticles with unique structural and biochemical characteristics.
Similar to Tumour markers with Recent Advances (20)
Gender and Mental Health - Counselling and Family Therapy Applications and In...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
How to Setup Warehouse & Location in Odoo 17 InventoryCeline George
In this slide, we'll explore how to set up warehouses and locations in Odoo 17 Inventory. This will help us manage our stock effectively, track inventory levels, and streamline warehouse operations.
ISO/IEC 27001, ISO/IEC 42001, and GDPR: Best Practices for Implementation and...PECB
Denis is a dynamic and results-driven Chief Information Officer (CIO) with a distinguished career spanning information systems analysis and technical project management. With a proven track record of spearheading the design and delivery of cutting-edge Information Management solutions, he has consistently elevated business operations, streamlined reporting functions, and maximized process efficiency.
Certified as an ISO/IEC 27001: Information Security Management Systems (ISMS) Lead Implementer, Data Protection Officer, and Cyber Risks Analyst, Denis brings a heightened focus on data security, privacy, and cyber resilience to every endeavor.
His expertise extends across a diverse spectrum of reporting, database, and web development applications, underpinned by an exceptional grasp of data storage and virtualization technologies. His proficiency in application testing, database administration, and data cleansing ensures seamless execution of complex projects.
What sets Denis apart is his comprehensive understanding of Business and Systems Analysis technologies, honed through involvement in all phases of the Software Development Lifecycle (SDLC). From meticulous requirements gathering to precise analysis, innovative design, rigorous development, thorough testing, and successful implementation, he has consistently delivered exceptional results.
Throughout his career, he has taken on multifaceted roles, from leading technical project management teams to owning solutions that drive operational excellence. His conscientious and proactive approach is unwavering, whether he is working independently or collaboratively within a team. His ability to connect with colleagues on a personal level underscores his commitment to fostering a harmonious and productive workplace environment.
Date: May 29, 2024
Tags: Information Security, ISO/IEC 27001, ISO/IEC 42001, Artificial Intelligence, GDPR
-------------------------------------------------------------------------------
Find out more about ISO training and certification services
Training: ISO/IEC 27001 Information Security Management System - EN | PECB
ISO/IEC 42001 Artificial Intelligence Management System - EN | PECB
General Data Protection Regulation (GDPR) - Training Courses - EN | PECB
Webinars: https://pecb.com/webinars
Article: https://pecb.com/article
-------------------------------------------------------------------------------
For more information about PECB:
Website: https://pecb.com/
LinkedIn: https://www.linkedin.com/company/pecb/
Facebook: https://www.facebook.com/PECBInternational/
Slideshare: http://www.slideshare.net/PECBCERTIFICATION
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
Communicating effectively and consistently with students can help them feel at ease during their learning experience and provide the instructor with a communication trail to track the course's progress. This workshop will take you through constructing an engaging course container to facilitate effective communication.
1. TUMOR MARKERS WITH RECENT
ADVANCES
DR. PRINCE LOKWANI
DEPT OF PATHOLOGY
SAIMS INDORE
GUIDED BY: DR.AMIT V. VARMA
2. What are Tumor Markers ?
Biological substances synthesized and released by
cancer cells themselves or
Produced by the host in response to the presence of
tumor
Most tumor markers are proteins
Detected in a solid tumor, in circulating tumor cells
in peripheral blood, in serum, lymph nodes, in bone
marrow, or in other body fluids .
3. Clinical applications of Tumour markers
In practice ,current tumour markers are useful for
evaluating progression of disease status after initial
therapy & for monitoring subsequent treatment
modalities.
4. Highly specific i.e. detectable in only one tumour , not detectable in
benign disease and healthy subjects
Highly sensitive i.e. detectable when only a few cancer cells are present
Specific to a particular organ
Correlate with the tumour stage or tumour mass
Correlate with the prognosis
Have a reliable prediction value
But ideal tumour marker doesn’t exists
Ideal Tumour Marker should be….
5. Cancer a multigene disease (cluster of diseases) which arises as a result of
mutational & epigenetic changes coupled with activation of complex signaling
networks.
It involves alteration of three main classes of genes – 1)Proto-oncogenes 2)Tumor
suppressor genes 3) DNA repair genes.
This contribute to development of cancer genotype & phenotype.
This alterations resist the natural & inherent death mechanisms embedded in
cells(apoptosis) coupled with dysregulation of cell proliferation events.
Cancer
6. These genetic alterations include gene rearrangements, point mutations & gene
amplifications leading to disturbances in molecular pathways regulating cell
growth, survival & metastasis.
When these changes manifest in majority of patients with specific type of
tumour this can be used as tumour markers (Biomarkers).
Can also be used for detection & developing targeted therapies besides
predicting responses to treatment.
7.
8.
9. Classification of Tumour markers
HormonesOncofetal AntigensEnzymesTumor-Associated ProteinsReceptorsGenetic
10.
11.
12.
13.
14.
15. HORMONES AS TUMOR MARKERS
ACTH :Cushing’s Syndrome ,lung Cancer
ADH :Lung , Adrenal Cortex , pancreatic
Bombesin :Lung
Calcitonin :Medullary Ca Thyroid
VIP : Pheochromocytoma, Neuroblastoma
HCG :Choriocarcinoma, Embryonal
16. ENZYMES AS TUMOR MARKERS
Prostatic Acid Phosphatase : Prostate
Alcohol Dehyrdrogenase & Aldolase : Liver Cancer
Alkaline Phosphatase : Bone, Liver, Leukemia
Neuron Specific Enolase : Small Cell Lung Cancer, Neuroblastoma,
Melanoma
Lactate Dehydrogenase : Lymphoma , Leukemia
17. ONCOFETAL ANTIGENS
AFP : Hepatocellular ,Germ Cell Tumor,
Carcino-fetal ferritin : Liver
CEA : Colorectal, Gastrointestinal, Lung, Breast ,Pancreatic
Squamous Cell Antigen : Cervical, Lung, Skin, Head & Neck
Tennessee Antigen : Colon, Gastrointestinal, Bladder
Cytokeratins :
1)Tissue Polypeptide Antigen : Breast, Colorectal, Ovarian, Bladder
2)Tissue Polypeptide Specific Antigen
3) Cytokeratin 19 Fragments (Cyfra-21-1) -A Prognostic marker for Non Small Cell Lung Cancer.
19. Nuclear Matrix Protein -22 : Bladder Cancer
S-100 Proteins - Melanoma
Autoantibodies to tumor antigens
Markers Of Angiogenesis : Vascular Endothelial Growth Factor (VEGF) ,
Soluble Tie 2 Receptor correlate with development of metastasis.
Thyroglobulin : Thyroid Cancer
Chromogranins : Neuroendocrine tumors
21. BLOOD GROUP ANTIGEN RELATED MARKERS
Ca 72-4 : Newer test for Ovarian, Pancreatic & Stomach Cancer (Studies of this marker are still
in progress)
Ca 19-9 : Pancreatic, Gastrointestinal, Hepatic .Best for Pancreatic Cancer.
Ca 19-5 : Pancreatic, Gastrointestinal , Ovarian
Ca 50 : Pancreatic, Gastrointestinal, Colon
Ca 242 : Pancreatic, Gastrointestinal
22. RECEPTORS & OTHER TUMOR MARKERS
Estrogen & Progesterone Receptors : Indicators of hormonal therapy in Breast Cancer.
Androgen Receptors : Prostate Cancer.
Hepatocyte Growth Factor Receptor (C-met) : Colorectal , Hepatocellular, Breast,
Prostate, Cervical Cancer.
Epidermal Growth Factor Receptors : Over expression has strong prognostic value.
23. Catecholamine Metabolites - VMA, HVA ,Metanephrines :Neuroblastoma ,
Pheochromocytoma
Hydroxyproline : Bone Metastasis ( Breast ), Multiple Myeloma
Lipid Associated Sailic Acid : Gastrointestinal ,Lung ,Rheumatoid
Polyamines
Lysophosphatidic Acid : A Potential biomarker for Ovarian & other
Gyneacological Cancers.
24. Viral Biomarkers
Hepatocellular cancer –
HBV promotes carcinogenesis through genetic instability generated by its common
integration in host DNA .
These markers include :
1. Analysis of viral DNA or proteins or antibodies produced against the viral proteins.
2.HBsAG
3.HBeAG
4.anti-HBV core-antigen.
5.anti-HBeAG, anti-HbsAG.
25. Cervical Cancer :
Persistent infection of high-risk type of human papilloma virus.
HPV-viral load in biopsy specimen.
Antibodies against HPV-E6 and E7 serves as markers of an invasive HPV associated
malignancy.
2 new HPV Vaccines “Gardasil” and “Cervarix” are highly immunogenic and effective in
preventing infections with high risk-HPV types 16 & 18.
EBV has been directly implicated in pathogenesis of Burkitt’s lymphoma, NHL,
nasopharyngeal carcinoma.
Detection of quantification of plasma EBV-DNA serves as a useful molecular marker for
diagnosis, monitoring and prediction of relapse in patients with nasopharyngeal
carcinoma and Hodgkin’s lymphoma.
26. Genetic markers
Deviations from diploid chromosome to Hypo & Hyper-diploidy as well as Aneuploidy
are noted in malignant tumors.
Sister chromatid exchanges & translocations give rise to structural aberrations are
scored using various Banding techniques. Philadelphia chromosome is associated with
CML due to translocation between chromosomes 9 & 22.
Double minutes & homogenously stained regions indicative of gene amplifications are
often observed in malignant cells that can serve as markers.
Somatic mutations are promising biomarkers for cancer risk as they can capture
genetic events associated with malignant transformations.
27. Enhanced cell proliferation ,most important hallmark of cancer can be assessed
by flow cytometric analysis of DNA content ,which is automated, objective &
rapid allowing large number of cells to be measured.
Identification of S phase cells & analysis of number of antigenic determinants of
proliferation (PCNA, Ki67, NOR, etc ) are studied by molecular cell biology
techniques which can be used as complementary markers.
Proteins encoded by mini chromosome maintenance genes (MCM) are also
proposed as useful markers of proliferation ; with high levels of gene expression
indicating poor prognosis.
28. Gene deletions can be discovered by PCR using microsatellite probes to various
chromosomes & sites .
Random chromosomal abnormalities are associated with clinical cancer.
Mutations & loss of heterozygosity within several proto-oncogenes can lead to
microsatellite instability
Detection of this MSI in pathological tissue samples & comparison with normal
tissue represents a valuable tool for early detection , at pre neoplastic stage.
29. Establishment of biomarkers require a comprehensive understanding of
molecular mechanisms & cellular processes underlying the initiation of
cancer, especially focusing on how small changes in only a few regulatory
genes or proteins can disrupt a variety of cellular functions.
In the post genomic era , with the availability of complete human genome
sequence & recent technological advancement such as high throughput DNA
sequencing , microarrays & mass spectrometry, the plethora of potentially
informative cancer biomarkers has expanded dramatically.
30. Oncogenes
Oncogenes are derived from proto-oncogenes that may be activated by dominant
mutations ,insertions , deletions, translocations , or inversions.
Most oncogenes code for proteins needed for proliferation & their activation leads to cell
division.
Most oncogenes are associated with hematologic malignancies ,such as leukemia & to a
lesser extent solid tumors .
More than 40 proto oncogenes are recognized but only few are useful as tumor markers.
31. RAS GENES
Proteins coded by RAS genes are located in inner face of cellular membranes.
They bind to GDP/GTP & function as molecular switches that regulate mitogenic
signals from growth factor to nucleus by signal transduction pathways .
These are activated in association with protein tyrosine kinase receptors
Mutated N RAS is critical step in carcinogenesis & is found in Neuroblastoma &
Acute myeloid leukemia
32. Single point mutation in K RAS at 12th position leads to change of amino
acid from glycine to valine in p21 protein & is most frequently found in
cancer & correlates with poor prognosis .
Mutations of RAS oncogenes have been detected in DNA in stool of
symptomatic & asymptomatic patients of colorectal cancer, suggesting a
novel ,noninvasive pattern for population screening.
ASCO in 2009 has formalized that diagnosis of metastatic colorectal cancer
with wild type K RAS tumors are likely to benefit from monoclonal
antibody treatments targeting the EGFR pathways such as CETUXIMAB &
PANITUMUMAB.
33. C- myc gene
Binds to DNA & is involved in transcription regulation.
Gene product p62 is located in nucleus of transformed cells.
Translocation results in activation of this gene & is associated with poor prognosis. Increased
expression is seen in T & B cell lymphoma ,sarcoma .
Over expression of p62 is also seen in 70 to 100% of primary breast cancers & can be detected
with immunohistochemistry.
34. Her-2/neu (ERBB2)
This gene codes for EGF family of tyrosine kinase receptors which are involved in cell
proliferation , differentiation & survival.
Amplification of this gene is found in Breast, Ovarian & gastrointestinal tumors.
HERCEPTIN treatment is administered only to those breast cancer patients who have
Her-2/neu amplification.
Immunohistochemistry is used to detect increased expression of this protein.
FISH is used for detection of HER-2/neu gene amplification.
35. BCL-2 GENE
BCL-2 oncogene codes for a protein which inhibits apoptosis, especially
lymphoma & leukemia cells.
Activation of this BCL-2 gene is due to 14:18 translocation resulting in formation
of BCL-2 protein.
Overexpression of BCL-2 gene is associated with development of resistance to
cytotoxic cancer chemotherapy .
36. BCR-ABL FUSION GENE
A balanced translocation between chromosomes 9 & 22 creating BCR- ABL fusion gene
( Philadelphia chromosome ) seen in 90% of CML patients.
Protein derived from this fusion is active tyrosine kinase that activates several signaling
pathways, leading to uncontrolled growth , inhibition of apoptosis & neoplastic
transformation.
Detection of BCR-ABL gene by RT-PCR is useful in diagnosing CML & monitoring residual
disease in patients who have undergone bone marrow transplantation.
Several strategies target the BCR-ABL gene by oligonucleotides or the BCR-ABL kinase
domain by tyrosine kinase inhibitor ST1571 (GLEEVEC OR IMATINIB MESYLATE )
37. Tumor suppressor genes
These genes are isolated from many solid tumors .
The oncogenicity of tumor suppressor genes is derived from loss of genes . Deletion
or Monosomy leads to loss of tumor suppressor genes
P53 gene activates molecular processes that delay the cell cycle progression of
proliferating cells & stimulate DNA repair process.
Mutant p53 gene is useful biomarker for predicting prognosis & patients response to
therapy.
Gene replacement therapies targeting p53 aims at restoration of p53 function in
cancer cells by introduction of exogenous p53.
APC gene is deactivated in many tumors (oesaphageal adenocarcinoma & squamous
cell carcinoma.) hypermethylated APC gene in the blood is associated with poor
survival.
38. Mutations in BRCA 1 & BRCA 2 gene have an inherited predisposition to
develop breast & ovarian cancer.
In colon cancer ,deletion or reduced expression of DCC gene correlates
with increasing stage & poor prognosis.
PTEN mutation or loss of expression is associated with more advanced
stage & is a poor prognostic indicator in various cancers, including
breast, cervical, hepatocellular & endometrial.
39.
40. New tumor markers include a broad range of biochemical entities such as:
1. nucleic acids
2. proteins
3. sugars
4. lipids
5. small metabolites
6. cytogenetic & cytokinetic parameters
7. whole tumor cells
8. cancer stem cells
41. ISOCITRATE DEHYDROGENASE 1
IDH1 can be used as a plasma biomarker for the diagnosis of NSCLCs,
particularly lung adenocarcinoma, with relatively high sensitivity and
specificity.
42. UROKINASE PLASMINOGEN ACTIVATOR SYSTEM
Contains 1) UROKINASE PLASMINOGEN ACTIVATOR (uPA) A serine protease
2) uPA membrane bound receptor (uPAR)
3) uPA inhibitors ,PAI-1 & PAI-2
Cathepsins B & L activates uPA ,which interacts with its receptor ,uPAR & converts plasminogen to
plasmin
Plasmin degrades extracellular matrix (ECM) components & activates MMPs which further degrade the
ECM & activate & release growth factors .
uPA is the prognostic marker in breast cancer. ALSO in ovarian ,renal ,cervical & other cancers.
It is measured by ELISA & commercially available kits for detection of uPA & PAI in tumor tissue.
43. CATHEPSINS
Are lysosomal proteases.
Cathepsin B , D L have role in tumor development & progression.
Expression & localization of CB & CD is altered in tumor tissue.
Increased expression is seen in –breast, gastric ,lung, prostate cancer & melanomas.
Altered localization is seen in –colon ,thyroid cancers ,-gliomas, breast epithelial tumors .
They are involved in tissue invasion through ECM degradation & growth promotion by various growth factors
–fibroblast growth factor ,Insulin like growth factor-1,Epidermal growth factor .
Increased expression of ECM proteases is seen in stromal cells at the border between tumor cells & normal
tissue .
Detection of CB & other growth factors in stromal cells & tumor tissue may have prognostic value. CB is
detected by ELISA.
44. MATRIX METALLO PROTEINASES
Zinc dependent endopeptidases capable of degrading components of ECM.
Involved in tissue remodeling & wound repair
Also associated with tumor growth ,invasion & metastasis.
Increased expression of MMP-2 & MMP-9 is associated with accelerated tumor progression in
oral carcinoma ,lung adenocarcinoma ,papillary thyroid carcinoma .
MMP-7 correlates with tumor aggressiveness in esophageal carcinoma.
Expression of MMP-1 is associated with lymph node metastasis in cervical cancer & peritoneal
metastasis in gastric cancer.
MMP inhibition may be therapeutic strategy for cancer.
MMPs are detected in tissue sections by immunohistochemistry using specific antibodies & in
tissue extracts & serum by immunoassay.
45. HEAT SHOCK PROTEINS
Physiopathological features of tumor micro environment (low glucose, oxygen)
stimulate HSP induction.
HSP 27 Expression is associated with poor prognosis in gastric ,liver ,prostate
carcinoma & osteosarcoma. Also associated with poor response to chemotherapy
in leukemia patients.
HSP 70 is correlated with poor prognosis in breast, endometrial, uterine ,cervical
& bladder carcinoma.
Implication of HSP in tumor progression & response to therapy has led to its
successful targeting in therapy by use of HSP in anticancer vaccines exploiting
their ability to act as immunological adjuvant.
46. MMP 13 –MATRIX METALLOPROTEIN 13
Potentially new tumor marker for breast diagnosis.
Gene expression using microarray technology was studied in breast cancer
patients .MMP 13 was 100% over expressed confirmed to be a secreted
protein by western blot analysis of the culture medium .
47. (HE4) HUMAN EPIDIDYMIS PROTEIN 4
Marker for ovarian cancer .
Gene for HE4 has been discovered using microarrays to be overexpressed in
epididymal tissue & later in ovarian cancer tissue.
The algorithm termed RISK OF MALIGNANCY INDEX (ROMI) incorporating
HE4 & CA 125 was accurate in classifying a high percentage of women with
epithelial ovarian cancer.
It is measured by enzyme immunoassay .
48. TUMOR ASSOCIATED TRYPSIN INHIBITOR(TATI)
Acute phase reactant & induced under strong inflammatory conditions
Increased in gastrointestinal & urologic cancers .
Useful marker for pancreatic cancer .
TATI in serum or urine is measured by radioimmunoassay.
49. Ova1 1ST IVDMIA PROTEOMIC DIAGNOSTIC FOR OVARIAN
CANCER.
Qualitative serum test that combines results of 5 immunoassays into a single numeric score.
5 markers are –CA 125, PREALBUMIN , Apo A1 , Transferrin & Beta 2 macroglobulin
Indicated in women who over age 18 & present with adnexal mass for which surgery is planned
& yet not referred to oncologist .
OVA1 score is calculated using OvaCalc software.
Expected value for probability of malignancy -
In premenopausal women-1)HIGH –OVA 1≥ 5.0 2) LOW OVA1 < 5.0
In postmenopausal women -1)HIGH –OVA 1≥ 4.4 2) LOW OVA1 < 4.4
50. Epigenetic markers
Epigenetic modifications occur directly through DNA methylation of genes or
indirectly by methylation ,acetylation or phosphorylation of histones & other
proteins around which DNA is wound to form chromatin.
Activity of DNA methyl transferases are altered in tumor cells & are associated with
developmental abnormalities.
Genomic hypo methylation leads to genomic instability & stronger gene
expression .
Local promoter( CpG )hypermethylation induces functional silencing of tumor
suppressor genes.
Hypermethylation of p16 promoter in the circulating serum DNA correlate well
with recurrent colorectal cancer.
51. Aberrant methylation of p16Ink4 & MGMT promoters can be detected in DNA
from the sputum of patients with squamous cell carcinoma nearly 3 years
before clinical diagnosis.
Alterations in methylation patterns of group of genes in sputum samples may
be an effective & non invasive approach for identifying smokers at risk of
developing lung cancer.
The development of therapeutics that reverse epigenetic alterations in cancer
cells along with prognostic & diagnostic assays on gene methylation patterns
are promising new avenues for future improvements in patient care.
52. Cells as Biomarkers
Circulating Tumor Cells [CTCs] :
They provide early and reliable indication of disease progression and survival of
patients on systemic therapy for metastatic breast cancer as early as 3-4 weeks after
initiation of therapy.
Superior to standard tumor markers in predicting prognosis.
Can be used as an early predictor of treatment efficacy and extremely in sparing
patients from futile therapy.
Can be detected by immunocytometry.
53. T-regulatory cells [CD4+,CD25+,Foxp3] :
These are important in inducing and maintaining peripheral self-tolerance and thus
preventing Immune pathologies.
Increased T regulatory activity is associated with poor response to tumor antigens and
contribute to immune dysfunction resulting in tumor growth.
T-regulatory cells may serve as surrogate immune marker of Cancer progression and
perhaps prognosis.
It is also useful as a predictor of response to therapies.
CD 90 is a diagnostic marker to differentiate between malignant pleural mesothelioma
& lung carcinoma with Immuno histochemistry .
54. Cancer Stem Cells [CSC] :
Subpopulation of cancer cells which resemble the developmental hierarchy of the
normal tissue from which the tumor arise.
Evidence for existence of CSC initially came from studies of AML.
CSC are now demonstrated in many solid tumors including glioblastoma,
medulloblastoma, breast cancer, melanoma and prostate cancer.
CSC are resistant to chemotherapy and radiation therapy. Eradication is the critical
determinant in achieving cure.
Identifying and characterizing CSC for every possible tumor is of paramount
importance and will likely lead to new therapeutic avenues.
55. (PCA 3) PROSTATE CANCER ANTIGEN 3 GENE
It is a new gene based test carried out on urine sample .
PCA 3 is highly specific to prostate cancer & NOT increased in benign
enlargement or inflammation of prostate.
This testing holds potential in men with elevated PSA levels but no
cancer on initial biopsy.
PCA 3 urine test will decide whether a new biopsy is needed.
56. Mitochondrial Markers
Mutations in mitochondrial DNA particularly in D-loop region have found in
many cancers .
Mutated mt DNA has been detected in body fluids of cancer patients & is
much more abundant than mutated nuclear p53 DNA.
57. Metabolic Biomarkers
Bio-energetic index of cell has been suggested for classification and prognosis
of cancer, besides predicting the response to therapy.
Positron emission tomography allows non invasive and quantitative analysis
of various biologic process.
It uses a glucose analogue [2-deoxy-D-glucose] labelled with positron emitter
Fluorine 18.
FDG that is partially metabolized and trapped as its phosphate [2-DG-6-P] in
the tumor tissue, thus, localizing the tumor
58. Extent of increase in glucose utilization measured by FDG-PET has been co-related
with degree of malignancy in some tumors.
Glycolytic inhibitors like 2-deoxy-D-glucose are selectively cytotoxic to tumor cells
sensitizing it to ionizing radiations. 2-DG has the potential to enhance the efficacy
of chemotherapy.
Clinical trials in patients with malignant brain tumors using a hypo fraction radio-
therapy protocol combined with 2DG have been very encouraging.
Studying cancer through metabolomics could reveal new biomarkers for cancer
that could be useful for its future prognosis ,diagnosis & therapy.
59. Therapeutic Biomarkers
Targeted therapies display greater selectivity for tumor cells. Eg : Small
molecule drugs that inhibit the activity of tyrosine kinases [ Eg : Imatinib and
Erlotinib targeting ABL & EGFR].
Antibody bevacizumab targets a growth factor that stimulates tumor blood
vessel growth.
60. Telomerase
One of the best markers for human cancer associated with only malignant tumors.
Telomerase enzyme ensures the maintenance of telomere and thereby protecting the cell
from degradation and cell death.
In cancer cells telomerase shuttling system is impaired.
The TRAP (telomeric repeat amplification protocol) assay is used for detection of telomerase
activity.
It has been a target for anti-cancer therapeutics that turn off telomerase and there by inhibit
tumor growth.
Currently two clinical trials : one using a vaccine [GRNVAC1] and the other a lapidated drug
[GRN163L] are under way to evaluate the efficacy of telomerase inhibitors.
61. Histone deacetylases [HDACs]
HDACs are associated with oncogenesis by regulating the expression of certain
tumor suppressor genes leading to excessive proliferation and
tumorogenesis.
They have recently been the attractive targets for cancer therapeutics.
HDAC inhibitors are currently under clinical investigation in a number of
hematological malignancies and solid tumors.
62. Mammalian target of rapamycin
Evolutionarily conserved serine threonine protein kinase that belongs to PIKK
(phosphoinositide 3 kinase (PI3K) –related kinase ) family .
Plays an important role regulating cell growth & proliferation .
Upon activation mTOR increases phosphorylation levels of its downstreams
targets that include P70S6K & 4EBP1, which leads to increased levels of
translation , ribosome biogenesis & reorganization of actin cytoskeleton &
inhibition of autophagy .
A no. of mTOR inhibitors have potent anti-proliferative properties which make
them useful for cancer chemotherapy particularly of advanced solid tumors
showing higher levels of expressions of phosphorylated S6.
63. PIN1Peptidyl-Prolyl-Isomerase [PPIase], PIN1 regulates post phosphorylation event which is
in the form Cis and Trans isomerization of phosphoserine/threonine – proline
peptide bonds at selective sides.
Over expression of PIN1 has been reported in human breast cancer cell lines and
tissues, and its expression closely correlates with the level of cyclin D1 in tumors.
PIN1 opens a new target for the development of specific therapeutics as phosphorylated
p53 is known substrates of PIN1.
Inhibition of PIN1 induces mitotic arrest and apoptosis in tumor cell lines
Recent studies with PIN1 inhibit or delays the growth of various tumor cell lines.
64. Proteomics analysis of saliva
Non invasive method for identifying biomarkers for human cancers
4 proteins in saliva have been found to be useful markers of oral cancers with 90% sensitivity
& 83% specificity for oral squamous cell carcinoma .
Calcium binding protein MRP 14
CD 59 –overexpressed on tumor cells that enables them to escape from complement
dependent & antibody mediated immune responses.
Profilin 1 a protein involved in several signaling pathways ,secreted in tumor
microenvironments during the early progressive stage of tumorogenesis.
Catalase, a member of antioxidative system is involved in carcinogenesis & tumor
progression .
65. ADIPONECTIN & LEPTIN – IN BREAST CANCER
Adiponectin & leptin are involved.
Studies show that leptin m RNA expression is higher than adiponectin m RNA
expression in cancer cells.
Adiponectin inhibits proliferation of cancer cells. Leptin stimulates growth of
cancer cells.
Adiponectin inhibits leptin induced cell proliferation.
66. ADHESION MOLECULES & METASTASISCell adhesion molecules, including Integrins, Selectins & Cadherins regulate
many steps of metastatic process.
Increased serum levels of E selectin, Inter cellular adhesion molecule (ICAM)
& Vascular adhesion molecule (VCAM) indicate late stage of Breast cancer or
the occurrence of metastasis & hence a poor prognosis.
67. Stress & cancer
Under normal circumstances trigerring ATF 3 gene in stressfull conditions
protects the body from harm by causing normal cells to commit suicide .
Cancer cells are able to switch on ATF 3 GENE in immune cells & causes
malfunction of immune cells & allows cancer cells to escape from the tumor
& spread to other parts of the body.
68. MICROARRAY BASED MARKERS
Amplichip p450 – Roche diagnostics
Oncotype Dx - Genomic health inc.
Mammaprint - Agendia inc.
Tissue of origin test – Pathwork diagnostics .
Bioplat-a software for human cancer biomarker discovery
Micro array based analytes will revolutionize the future of cancer therapy by providing
biomarkers on their genetic makeup.
69. The preclinical strategy of cancer biomarker discovery are sensitive &
specific enough
-For early cancer detection
-For monitoring disease progression &
-For proper treatment selection,
paving the way to individualized cancer treatment.
New era in clinical oncology will be guided by molecular attributes of
individual patients that will also answer about biologic behavior of
tumors .
70. PARANEOPLASTIC SYNDROME
Paraneoplastic syndrome is a disease or a symptom that is a consequence
of cancer, but not due to the presence of local cancer cells.
Paraneoplastic syndrome is mediated through:
Cross reacting antibodies
Production of physiologically active factors
Interference with normal metabolic pathways
idiopathic
71. PARANEOPLASTIC SYNDROME
Paraneoplastic syndrome is a disease or a symptom that is a
consequence of cancer, but not due to the presence of local cancer
cells.
All neurological abnormalities Not Caused By:
Invasion by the tumor or its metastases
Infections
Ischemia, metabolic or nutritional deficits
Surgery or other treatment modalities
“Remote effects of cancer on the nervous system”
72. Paraneoplastic Syndromes May Affect Any Portion of the
Nervous System
Cerebral cortex
Brainstem
Spinal cord
Peripheral nerves
Neuromuscular junction
Muscle